Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. | Semantic
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC | Nature Reviews Clinical Oncology
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy | Oncology Practice Management
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients - ScienceDirect
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology
Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram
ASCO 2022: Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
2021 Midyear Review: Non–Small-Cell Lung Cancer | Personalized Medicine in Oncology
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA | SpringerLink
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
Update Confirms 5-Year Survival Benefit With Dual Immune Checkpoint Blockade in NSCLC
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
JTO & JTO CRR on Twitter: "In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival versus chemotherapy in patients w/tumor programmed death-ligand 1 greater than or equal to 1% (primary end point)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
Bristol might play a role in front-line lung cancer after all | Evaluate
US regulator scoops Asco with Bristol's lung cancer approval | Evaluate
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients☆ - ESMO Open
ESMO 2022: Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
Rapid Readouts: Three-Year Update From CheckMate 227, Part 1
Kaplan-Meier curves after matching adjustment for (A) overall survival... | Download Scientific Diagram
